Biosynthetic RPE monolayer for advanced dry AMD feasible, well-tolerated

CHICAGO — It is feasible and safe to surgically implant an investigational human embryonic stem cell derived RPE monolayer on an ultrathin synthetic substrate to treat severe vision loss from geographic atrophy in patients with advanced dry age-related macular degeneration, according to a speaker here.
“Targeted delivery of implants to the subretinal space is very feasible in an outpatient basis, and intraoperative OCT was particularly useful but not absolutely necessary for identifying pathology and implant placement,” Amir H. Kashani, MD, PhD, said at the American Society

Full Story →